Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles.

May T, Shoni M, Crum CP, Xian W, Vathipadiekal V, Birrer M, Rosen B, Tone A, Murphy KJ.

Gynecol Oncol. 2013 Mar;128(3):488-92. doi: 10.1016/j.ygyno.2012.12.009. Review.

PMID:
23253401
2.

Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.

Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Shih IM, Bristow RE.

Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6.

PMID:
17504374
3.

Quantification of ER/PR expression in ovarian low-grade serous carcinoma.

Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Köbel M.

Gynecol Oncol. 2013 Feb;128(2):371-6. doi: 10.1016/j.ygyno.2012.10.013.

PMID:
23103384
4.

Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.

Zhu YF, He LS, Zhang ZD, Huang QS.

Asian Pac J Trop Med. 2012 Dec;5(12):925-30. doi: 10.1016/S1995-7645(12)60175-8.

5.

The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin.

Kessler M, Fotopoulou C, Meyer T.

Int J Mol Sci. 2013 Mar 25;14(4):6571-96. doi: 10.3390/ijms14046571. Review.

6.

Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.

Maxwell GL, Chandramouli GV, Dainty L, Litzi TJ, Berchuck A, Barrett JC, Risinger JI.

Clin Cancer Res. 2005 Jun 1;11(11):4056-66.

7.

Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.

Hasby EA.

Tumour Biol. 2016 Apr;37(4):4889-900. doi: 10.1007/s13277-015-4333-y.

PMID:
26526579
8.

[Serous ovarian tumors].

Diebold J.

Pathologe. 2014 Jul;35(4):314-21. doi: 10.1007/s00292-014-1906-2. Review. German.

PMID:
24916775
9.

Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.

Ali RH, Kalloger SE, Santos JL, Swenerton KD, Gilks CB.

Int J Gynecol Pathol. 2013 Nov;32(6):529-35. doi: 10.1097/PGP.0b013e31827630eb.

PMID:
24071867
10.

Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.

Darb-Esfahani S, Fritzsche F, Kristiansen G, Weichert W, Sehouli J, Braicu I, Dietel M, Denkert C.

Virchows Arch. 2012 Aug;461(2):109-16. doi: 10.1007/s00428-012-1273-4.

PMID:
22752467
11.

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A; Australian Ovarian Cancer Study (AOCS)..

Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Erratum in: Clin Cancer Res. 2016 Aug 15;22(16):4272.

12.

Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.

May T, Virtanen C, Sharma M, Milea A, Begley H, Rosen B, Murphy KJ, Brown TJ, Shaw PA.

Gynecol Oncol. 2010 Apr;117(1):9-17. doi: 10.1016/j.ygyno.2010.01.006.

PMID:
20117829
13.

Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.

Djordjevic B, Malpica A.

Am J Surg Pathol. 2012 Jul;36(7):955-63. doi: 10.1097/PAS.0b013e31825793e1.

PMID:
22613998
14.

Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases.

Gallardo A, Matias-Guiu X, Lagarda H, Catasus L, Bussaglia E, Gras E, Suarez D, Prat J.

Int J Gynecol Pathol. 2002 Jul;21(3):268-72.

PMID:
12068173
15.

Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.

Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D.

Gynecol Oncol. 2008 Sep;110(3):408-17. doi: 10.1016/j.ygyno.2008.05.010.

PMID:
18597838
16.

[Fallopian tube: the dark face of pelvic carcinogenesis].

Watkin E, Devouassoux-Shisheboran M.

Ann Pathol. 2011 Oct;31(5):345-52. doi: 10.1016/j.annpat.2011.06.008. Review. French.

PMID:
21982240
17.

[The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].

Chêne G, Dauplat J, Radosevic-Robin N, Cayre A, Penault-Llorca F.

Bull Cancer. 2013 Jul-Aug;100(7-8):757-64. doi: 10.1684/bdc.2013.1785. French.

PMID:
23831931
18.

Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).

Delair D, Soslow RA.

Histopathology. 2012 Sep;61(3):329-39. doi: 10.1111/j.1365-2559.2011.04167.x. Review.

PMID:
22372521
19.

A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2012 Jun;125(3):655-60. doi: 10.1016/j.ygyno.2012.02.028.

20.

Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.

Okoye E, Euscher ED, Malpica A.

Am J Surg Pathol. 2016 May;40(5):627-35. doi: 10.1097/PAS.0000000000000615.

PMID:
26900814

Supplemental Content

Support Center